Treatment options for asthma attacks
Pro Research Analysisby 
Searched over 200M research papers
Standard Treatments for Asthma Attacks: Inhaled Bronchodilators and Systemic Corticosteroids
The primary treatment options for acute asthma attacks (exacerbations) are inhaled bronchodilators, such as short-acting β2 agonists (SABAs), and systemic corticosteroids. These medications are used early during an attack to quickly relieve airway constriction and reduce inflammation, which helps lower the risk of hospitalization and further complications 578. Short-acting muscarinic antagonists and oxygen therapy may also be used as needed during severe episodes .
Maintenance and Prevention: Inhaled Corticosteroids and Combination Therapies
For long-term control and prevention of asthma attacks, inhaled corticosteroids (ICS) are the mainstay of therapy for most patients with persistent asthma. When symptoms are not adequately controlled with ICS alone, long-acting β2 agonists (LABAs) or long-acting muscarinic antagonists (LAMAs) can be added. Combination inhalers containing both ICS and LABA are commonly used to improve symptom control and reduce the frequency of attacks 2458.
As-Needed and SMART/MART Therapies
Recent evidence supports the use of as-needed therapies, such as ICS/LABA combinations, for both maintenance and relief (known as SMART or MART therapy). These regimens have been shown to be effective in reducing the risk of exacerbations in both mild-to-moderate and moderate-to-severe asthma, and are generally well tolerated . As-needed therapy with ICS/LABA is now considered a suitable and effective option for many patients .
Biologic Therapies for Severe Asthma Attacks
For patients with severe asthma who do not respond well to standard treatments, biologic therapies have become important options. These include monoclonal antibodies targeting specific inflammatory pathways, such as anti-IgE (omalizumab), anti-IL-5 (mepolizumab, reslizumab), anti-IL-5R (benralizumab), and anti-IL-4R (dupilumab). These biologics are particularly beneficial for patients with severe, eosinophilic, or allergic asthma phenotypes, helping to reduce exacerbations, improve lung function, and decrease the need for oral corticosteroids 1345+1 MORE.
Additional and Emerging Treatment Options
Other add-on therapies for asthma management include leukotriene receptor antagonists, sustained-release theophylline, and allergen immunotherapy. For patients with severe, uncontrolled asthma, bronchial thermoplasty—a procedure that reduces airway smooth muscle mass—may be considered, especially in those with chronic airflow obstruction 456. New therapies in development include additional anti-interleukin agents, phosphodiesterase-4 inhibitors, and novel LAMAs, which may further expand treatment options in the future 16.
Personalized and Phenotype-Driven Approaches
There is a growing emphasis on personalizing asthma treatment based on individual patient characteristics and asthma phenotypes. This approach aims to optimize therapy, minimize side effects, and improve outcomes by targeting the specific underlying mechanisms driving each patient’s asthma attacks 47.
Conclusion
Asthma attack treatment relies on rapid-acting bronchodilators and systemic corticosteroids for immediate relief, with inhaled corticosteroids and combination therapies for long-term control. For severe or difficult-to-treat cases, biologic therapies and other advanced options are available. Ongoing research and a personalized approach continue to improve the management and outcomes of asthma attacks 1234+6 MORE.
Sources and full results
Most relevant research papers on this topic
Emerging therapeutic options for the treatment of patients with symptomatic asthma.
Emerging therapies like tiotropium show promise as an effective add-on to inhaled corticosteroid maintenance therapy for patients with symptomatic asthma.
DOI